There isn’t a single, universal “market share” figure for interferon beta drugs. Shares vary by region (global vs. US vs. Europe), by year, and by whether you’re measuring revenue, prescriptions, or units. In general:
- Interferon beta products (Avonex, Rebif, Betaseron/Extavia, Plegridy) have seen their market share decline over the past decade as newer MS disease-modifying therapies (DMTs) have gained prominence.
- In many markets today, interferon beta drugs are a minority of MS DMT sales—often in the single digits to low double digits in revenue. In some regions with longer use of traditional therapies, they can still be more significant, but they’re usually not the majority.
- The largest MS DMTs by revenue in recent years have been agents like ocrelizumab, fingolimod, dimethyl fumarate, natalizumab, teriflunomide, and others; interferon beta products tend to rank lower in revenue share.
If you want precise numbers, tell me:
- Region (global, US, EU, or another region)
- Time period (year or range, e.g., 2022–2023)
- Metric (revenue share, prescription share, or unit share)
I can then pull or summarize the latest figures from market research reports and give you a region-specific breakdown.